Comparisons to FDA-approved medications in this article describe pharmacological similarity, not therapeutic interchangeability.
Alcohol use disorder (AUD) remains a leading cause of preventable death among veterans. GLP-1 receptor agonists, widely used for diabetes and weight loss, have shown unexpected reductions in alcohol intake in observational studies. P21, a peptide derived from cerebrolysin, may enhance neurotrophic signaling and synaptic repair. This article outlines a randomized controlled trial (RCT) design to test intranasal P21 in GLP-1-using veterans with AUD, leveraging the VA's national research infrastructure.
Why Target Veterans on GLP-1s?
Veterans have high rates of AUD and metabolic comorbidities. GLP-1 agonists such as semaglutide reduce alcohol consumption in preclinical models and retrospective human data. A VA-based trial can recruit from a large, well-characterized population with integrated electronic health records. The VA's Million Veteran Program and centralized IRB streamline multisite studies. Enrollment of 200 participants across 10 VA sites is feasible within 18 months.
P21 Mechanism and Rationale
P21 is a synthetic peptide mimicking the neurotrophic effects of cerebrolysin. It binds to the CNTF receptor complex, activating STAT3 and AKT pathways (Sikiric 2018). This promotes neuronal survival and synaptic plasticity. In animal models, P21 enhances hippocampal neurogenesis and reduces alcohol-seeking behavior. Intranasal delivery bypasses the blood-brain barrier, achieving rapid brain concentrations. Prior work on quantifying P21 uptake in neuronal cells after intranasal delivery confirms its bioavailability.
Step 1: Crossover Design with Semax Co-Administration
Semax, a nootropic peptide, may synergize with P21 by enhancing BDNF expression. A crossover phase can assess pharmacokinetic interactions. Participants receive intranasal P21 alone, Semax alone, and combined, with washout periods. This design controls for individual variability. Our recent validation of P21 co-administration with Semax provides a framework. Cerebrospinal fluid sampling at 30, 60, and 120 minutes post-dose will measure peptide levels. A pilot with 24 subjects can detect a 30% difference in AUC with 80% power.
Step 2: Dose-Finding and Safety Run-In
An open-label dose escalation in 30 veterans establishes the maximum tolerated dose. Starting at 0.5 mg/kg daily, doses increase every 2 weeks. Adverse events are graded by CTCAE v5.0. Nasal irritation, headache, and nausea are expected. The primary safety endpoint is treatment-emergent adverse events at 4 weeks. Stable GLP-1 dosing is required for 3 months prior. This phase also assesses compliance using electronic monitors. A 20% dropout rate is assumed based on prior VA addiction trials.
Step 3+: Randomized Double-Blind Phase
Eligible veterans are randomized 1:1 to intranasal P21 or placebo for 12 weeks. Stratification factors include GLP-1 type and baseline heavy drinking days. The primary efficacy outcome is percent change in heavy drinking days, measured by timeline followback. Secondary outcomes include craving scores, gamma-glutamyl transferase, and BDNF serum levels. A sample of 200 provides 85% power to detect a 15% absolute reduction in heavy drinking days. Neuroimaging substudies will assess hippocampal volume changes. Stability of the formulation is critical; our P21 peptide stability validation ensures 6-month shelf life.
Implications for Outcomes
If P21 shows efficacy, it could address a major unmet need. Veterans with AUD often have cognitive deficits that impair recovery. Neurotrophic support may improve executive function and reduce relapse. The VA's integrated care model allows long-term follow-up for sustained drinking outcomes. Cost-effectiveness will be evaluated using VA health utilization data. A positive trial would support a new class of addiction therapeutics.
Evidence Quality Summary
The proposed trial builds on strong preclinical evidence and leverages a robust clinical network. Limitations include potential unblinding due to nasal sensations and heterogeneity in GLP-1 adherence. The crossover phase mitigates pharmacokinetic variability. Independent data monitoring and standardized training ensure rigor. This design balances feasibility with scientific validity, aiming to produce actionable evidence for veteran care.